NOT-OD-24-090: Notice of Participation of the Office of Research on Women's Health (ORWH) in PAR-23-102, "Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)"

Notice of Participation of the Office of Research on Women's Health (ORWH) in PAR-23-102, "Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)"

Notice Number:

NOT-OD-24-090

Key Dates

Release Date:

March 28, 2024

Related Announcements

January 13, 2023 - Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional). See NOFO PAR-23-102

Issued by

Office of Research on Women's Health (ORWH)

Purpose

The purpose of this notice is to inform potential applicants that the Office of Research on Women's Health (ORWH) will participate, effective June 16, 2024 , in PAR-23-102, "Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)"

______________________________________________________________________________

Part 1. Overview Information

The following information has been added.

Components of Participating Organizations

Office of Research on Women's Health (ORWH)

Catalog of Federal Domestic Assistance (CFDA) Number(s):

93.313

Part 2. Section VII. Agency Contacts

The following contacts have been added:

Scientific/Research Contact(s):

Sarah M. Temkin, MD
Office of Research on Women's Health (ORWH)
Phone: 301-485-6828
Email: [email protected]

All other aspects of the NOFO remain the same.

Inquiries

Please direct all inquiries to:

Sarah M. Temkin, MD
Office of Research on Women's Health (ORWH)
Phone: 301-485-6828
Email: [email protected]